medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2017, Número 3

<< Anterior Siguiente >>

Rev Invest Clin 2017; 69 (3)


Risk Factors for No-Reflow Phenomenon after Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome

Liang T, Liu M, Wu C, Zhang Q, Lu L, Wang Z

Idioma: Ingles.
Referencias bibliográficas: 24
Paginas: 139-145
Archivo PDF: 70.32 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Tobis J. Is no-no-reflow following PCI in AMI due to distal embolization of plaque and thrombus? Catheter Cardiovasc Interv. 2013;82:210-1.

  2. Arslan U, Yaman M, Kocaog˘lu I˙, et al. Risk of no-reflow in culprit lesion versus culprit vessel PCI in acute STEMI. Coron Artery Dis. 2015;26:510-5.

  3. Gupta S, Gupta MM. No reflow phenomenon in percutaneous coronary interventions in ST-segment elevation myocardial infarction. Indian Heart J. 2016;68:539-51.

  4. Kim MC, Cho JY, Jeong HC, et al. Long-term clinical outcomes of transient and persistent no reflow phenomena following percutaneous coronary intervention in patients with acute myocardial infarction. Korean Circ J. 2016;46:490-8.

  5. Wang L, Liu G, Liu J, Zheng M, Li L. Effects of no-reflow phenomenon on ventricular systolic synchrony in patients with acute anterior myocardial infarction after percutaneous coronary intervention. Ther Clin Risk Manag. 2016;12:1017-22.

  6. Yang L, Mu L, Sun L, Qi F, Guo R. Effect of intracoronary nitroprusside injection time point on flow recovery during primary percutaneous coronary intervention in patients with ST elevation acute myocardial infarction. Minerva Cardioangiol. 2017;65:111-18.

  7. Leonardi S, Lopes RD, Steg PG, et al. Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience. Eur Heart J Acute Cardiovasc Care. 2016. (Epub ahead of print).

  8. Amano H, Ikeda T, Toda M, et al. Plaque composition and noreflow phenomenon during percutaneous coronary intervention of low-echoic structures in Grayscale intravascular ultrasound. Int Heart J. 2016;57:285-91.

  9. Reffelmann T, Kloner RA. The no-reflow phenomenon: basic science and clinical correlates. Heart. 2002;87:162-8.

  10. Ipek G, Gungor B, Karatas MB, et al. Risk factors and outcomes in patients with ectatic infarct-related artery who underwent primary percutaneous coronary intervention after ST elevated myocardial infarction. Catheter Cardiovasc Interv. 2016;88: 748-53.

  11. Sensoy B, Uzunget SB, Acikgoz S, et al. Renal dysfunction on admission predicts no-reflow phenomenon in patients undergoing manual thrombus aspiration during primary percutaneous coronary intervention. Acta Cardiol Sin. 2016;32:185-93.

  12. Suda A, Namiuchi S, Kawaguchi T, et al. A simple and rapid method for identification of lesions at high risk for the no-reflow phenomenon immediately before elective coronary stent implantation. Heart Vessels. 2016;31:1904-14.

  13. Levi Y, Sultan A, Alemayehu M, Wall S, Lavi S. Association of endothelial dysfunction and no-reflow during primary percutaneous coronary intervention for ST-elevation myocardial infarction. Cardiovasc Revasc Med. 2016;17:552-5.

  14. Balta S, Celik T, Ozturk C, et al. The relation between monocyte to HDL ratio and no-reflow phenomenon in the patients with acute ST-segment elevation myocardial infarction. Am J Emerg Med. 2016;34:1542-7.

  15. Wagdy S, Sobhy M, Loutfi M. Neutrophil/lymphocyte ratio as a predictor of in-hospital major adverse cardiac events, new-onset atrial fibrillation, and no-reflow phenomenon in patients with ST elevation myocardial infarction. Clin Med Insights Cardiol. 2016; 10:19-22.

  16. Murat SN, Kurtul A, Celik IE, et al. The association of serum procalcitonin level with the no-reflow phenomenon after a primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction. Coron Artery Dis. 2016;27: 116-21.

  17. Falk E, Thuesen L. Pathology of coronary microembolisation and no reflow. Heart. 2003;89:983-5.

  18. Nukada H, Anderson GM, McMorran PD. Reperfusion nerve injury: pathology due to reflow and prolonged ischaemia. J Peripher Nerv Syst. 1997;2:60-9.

  19. Dong M, Mu N, Ren F, Li F, Zhang C, Yang J. Matrix metalloproteinase- 9 in the culprit coronary artery and myocardial no-reflow. Am J Med Sci. 2015;350:352-6.

  20. Li J, Wu L, Tian X, Zhang J, Shi Y. Intravascular ultrasound observation of the mechanism of no-reflow phenomenon in acute myocardial infarction. PLoS One. 2015;10:e0119223.

  21. Yip HK, Chen MC, Chang HW. Angiographic morphologic features of infarct-related arteries and timely reperfusion in acute myocardial infarction: predictors of slow-flow and no-flow. Chest. 2002;122:1322-32.

  22. De Luca G, Suryapranata H, Zijlstra F. Symptom-onset-to-balloon time and mortality in patients with acute myocardial infarction treated by primary angioplasty. J Am Coll Cardiol. 2003; 42:991-7.

  23. Ishikura F, Miki A, Iwata A. Effect of systemic blood pressure in microcollateral circulation evaluated by real-time contrast echocardiography. J Am Soc Echocardiogr. 2008;21:765-9.

  24. Lee KL, Woodlief LH, Topoi EJ. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: results from an international trial of 41021 patients. GUSTO-Investigators. Circulation. 1995;91:1659-68.




2020     |     www.medigraphic.com